Technologies
PDF


WARF: P160179US01

Growth Factor Regulation in Blood Products for Improved Wound Healing


INVENTORS -

William Murphy, David Belair, Ngoc Nhi Le, Michael Toepke, Nicholas Impellitteri, Connie Chamberlain

The Wisconsin Alumni Research Foundation (WARF) is seeking commercial partners interested in developing hydrogel microspheres that selectively remove VEGF from blood products prior to clinical use.
OVERVIEWGrowth factor regulation is a key function of the extracellular matrix and critical for proper blood vessel growth and maturation during wound healing. In particular, blood vessel sprouting is essential for effective healing and dependent on the well-regulated activity of vascular endothelial growth factor (VEGF). Research has shown that blood vessel sprouting can only occur within a limited VEGF concentration range in vivo.

The need to maintain VEGF activity within a particular concentration range during angiogenesis has motivated the search for therapeutic interventions when natural regulation is dysfunctional, such as during diabetic wound healing and tumor growth. Unregulated VEGF activity can result in hemangioma formation and is linked to poor musculoskeletal wound healing, ocular disease and other health concerns.
THE INVENTIONUW–Madison researchers have developed hydrogel microspheres for sequestering problematic growth factors, specifically VEGF, in patient-derived blood products. The degradable microspheres are functionalized with peptide ligands that selectively bind and remove unwanted VEGF from platelet rich plasma and other blood products before they are used in clinical procedures.
APPLICATIONS
  • Medical device for the purification of autologous blood products and/or clinical delivery of products that have been selectively altered
  • Common uses of platelet-derived growth factors include wound healing and recovery from sports-related injuries.
KEY BENEFITS
  • Lower cost and more convenient that existing antibody-based approaches
  • Enables intraoperative processing of blood products prior to clinical use
STAGE OF DEVELOPMENTThe researchers have fabricated poly(ethylene glycol) microspheres with VEGF-binding peptide and demonstrated their efficacy in sequestering/reducing the activity of VEGF from patient-derived platelets.
ADDITIONAL INFORMATION
For More Information About the Inventors
Contact Information
For current licensing status, please contact Jeanine Burmania at jeanine@warf.org or 608-960-9846.
The WARF Advantage

Since its founding in 1925 as the patenting and licensing organization for the University of Wisconsin-Madison, WARF has been working with business and industry to transform university research into products that benefit society. WARF intellectual property managers and licensing staff members are leaders in the field of university-based technology transfer. They are familiar with the intricacies of patenting, have worked with researchers in relevant disciplines, understand industries and markets, and have negotiated innovative licensing strategies to meet the individual needs of business clients.